GAF Healthcare
Обзор направления

Лучшие больницы для «Bile Duct Cancer Treatment» в ОАЭ

3 больниц по направлению «Медицинская онкология» представлены в нашей сети в ОАЭ, с аккредитацией Hospital Certificates of Services, JCI.

3
больниц в списке
1
город
4.5
средний рейтинг
2
вида аккредитации
Короткий ответ

На этой странице перечислены больницы направления «Медицинская онкология» (включая Bile Duct Cancer Treatment) в ОАЭ, включая Burjeel Hospital for Advanced Surgery Dubai, Kings College Hospital Dubai, Aster Hospital Dubai.

Спросите нас о «Bile Duct Cancer Treatment» в ОАЭ

Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.

Сравните 3 аккредитованных больниц (Медицинская онкология) в ОАЭ

🇦🇪 Burjeel Hospital for Advanced Surgery Dubai

Dubai, UAE 4.5 (1 отзывов) 209 коек
Почему стоит выбрать эту больницу?
Рейтинг 4.5 из 5 (1 отзывов)Аккредитация: Hospital Certificates of Services209 коек
Специализации и аккредитация
OrthopedicsCardiac SciencesCosmetic SurgeryGastroenterologyGeneral SurgeryGynecology
Аккредитация Hospital Certificates of Services
Полный профиль →
4.5/5
Рейтинг
2014
Основана в
209
Койки
Dubai, UAE
Расположение
Kings College Hospital Dubai

🇦🇪 Kings College Hospital Dubai

Dubai, UAE 4.5 (1 отзывов) 100 коек
Почему стоит выбрать эту больницу?
Рейтинг 4.5 из 5 (1 отзывов)Аккредитация: Hospital Certificates of Services100 коек
Специализации и аккредитация
Cardiac SciencesCosmetic SurgeryENTGastroenterologyGeneral SurgeryGynecology
Аккредитация Hospital Certificates of Services
Полный профиль →
4.5/5
Рейтинг
2014
Основана в
100
Койки
Dubai, UAE
Расположение
Aster Hospital Dubai

🇦🇪 Aster Hospital Dubai

Dubai, UAE 4.5 (1 отзывов) 114 коек
Почему стоит выбрать эту больницу?
Рейтинг 4.5 из 5 (1 отзывов)Аккредитация: JCI114 коек
Специализации и аккредитация
BariatricCardiac SciencesCosmetic SurgeryENTGastroenterologyGeneral Surgery
Аккредитация JCI
Полный профиль →
4.5/5
Рейтинг
1987
Основана в
114
Койки
Dubai, UAE
Расположение
Наша методология

Как мы выбираем эти больницы

Больница появляется на этой странице, если направление «Медицинская онкология» указано среди её специализаций и она находится в ОАЭ. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».

На что обратить внимание

Как выбрать лучшую больницу для «bile duct cancer treatment» в ОАЭ?

Выбор подходящей больницы для «bile duct cancer treatment» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:

Международная аккредитация

Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.

Специализация

Убедитесь, что в больнице есть отделение, специализирующееся на «Медицинская онкология», а не только общая помощь.

Мощность и опыт

Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.

Прозрачность стоимости

Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.

Клинический обзор

Что нужно знать о процедуре «Bile Duct Cancer Treatment»

Bile duct cancer (cholangiocarcinoma) is a rare but aggressive malignancy arising from the epithelial cells lining the biliary tract, requiring a highly specialized multidisciplinary approach that integrates hepatobiliary surgery, interventional oncology, and precision medicine. With curative resection rates of 25–40% in resectable cases and improving 5-year survival outcomes through advanced targeted therapies such as IDH1 inhibitors and FGFR2 inhibitors, patients worldwide are achieving better results at internationally accredited centers. GAF Healthcare connects international patients with leading JCI- and NABH-accredited oncology hospitals in India and JCI- and DHA-accredited centers in the UAE, offering expert-level biliary oncology care at a fraction of Western costs, with comprehensive end-to-end medical tourism coordination.

10–21 days (varies by surgical complexity and adjuvant treatment phase)
Hospital Stay
4–8 weeks (longer for major hepatic resection; shorter for palliative stenting or systemic therapy initiation)
Total Stay in Country (Fit-to-Fly)
Curative resection: 25–40% long-term disease-free survival; palliative/systemic therapy disease control rate: 50–65%
Success Rate

Clinical Overview

Cholangiocarcinoma (bile duct cancer) originates from cholangiocytes — the epithelial cells lining the intrahepatic, perihilar (Klatskin tumor), or distal extrahepatic bile ducts. It is classified anatomically as intrahepatic (iCCA), perihilar (pCCA), or distal cholangiocarcinoma (dCCA), each with distinct surgical approaches, staging systems, and molecular profiles. The Bismuth-Corlette classification remains the cornerstone for stratifying perihilar tumors (Types I–IV), directly determining resectability and the extent of hepatic resection required. Physiologically, tumor growth causes progressive biliary obstruction, leading to cholestasis, jaundice, pruritis, malabsorption of fat-soluble vitamins, coagulopathy due to impaired vitamin K absorption, and, in advanced cases, biliary sepsis and liver failure. Elevated serum bilirubin, alkaline phosphatase, CA 19-9, and CEA are common biochemical hallmarks, though CA 19-9 lacks specificity and must be interpreted alongside cross-sectional imaging.

Подробнее →

Who is a Candidate?

  • ELIGIBLE FOR SURGICAL RESECTION (Curative Intent):
  • Patients with anatomically resectable intrahepatic, perihilar, or distal bile duct tumors confirmed on MRCP and CECT
  • Adequate future liver remnant (FLR): minimum 25–30% in normal liver, 40% in cirrhotic or post-chemotherapy liver (assessed by volumetric CT)
  • No radiological evidence of distant metastases on PET-CT
  • ECOG Performance Status 0–1
  • +30 more

Treatment Options & Approaches

SURGICAL APPROACHES (Curative Intent):

1. Extended Hepatectomy with Bile Duct Excision (Perihilar / Intrahepatic CCA):

The most complex hepatobiliary procedure, involving right or left hepatectomy (often extended to segments I, IV, V, VIII), complete extrahepatic bile duct excision, regional lymphadenectomy, and Roux-en-Y hepaticojejunostomy reconstruction. Vascular resection and reconstruction of the portal vein or hepatic artery may be required in select Bismuth-Corlette Type III/IV tumors. The caudate lobe (segment I) is routinely resected for perihilar CCA given its dual biliary drainage. Intraoperative frozen section analysis of bile duct margins is mandatory to confirm R0 status.

2. Pancreaticoduodenectomy / Whipple Procedure (Distal CCA):

Подробнее →

Восстановление

PRE-OPERATIVE / PRE-TREATMENT PHASE (Weeks 1–4 before intervention):

Step 1 — Remote Case Evaluation (Before Travel):

Patient submits existing imaging (CT, MRI, MRCP, PET-CT), histopathology reports, blood work, and operative records (if any) to GAF Healthcare. Assigned hepatobiliary oncology multidisciplinary team (MDT) reviews the case. A detailed second-opinion report, treatment plan, and itemized cost estimate are provided within 72 hours.

Подробнее →

Возможные риски

Bile duct cancer treatment carries a spectrum of procedure-specific and oncology-related risks that must be contextualized honestly. For major hepatectomy and bile duct excision, the most serious risks include post-hepatectomy liver failure (PHLF) — occurring in up to 8–10% of extended resections — which carries significant mortality if ISGLS Grade C is reached; bile leak (Grade B/C in 5–15% of cases, requiring percutaneous drainage or re-exploration); post-operative biliary stricture at the hepaticojejunostomy anastomosis (long-term risk of 5–10%); intra-abdominal hemorrhage; and septic cholangitis. Pancreaticoduodenectomy for distal CCA carries the additional risks of delayed gastric emptying (DGE, 15–25%), post-operative pancreatic fistula (POPF, 10–20%), and marginal ulceration. Perioperative mortality at high-volume centers is approximately 2–5% for major hepatic resections.

Подробнее →

Почему GAF Healthcare

GAF Healthcare provides comprehensive non-medical coordination services that begin the moment a patient initiates contact and continue through long-term post-treatment follow-up, regardless of whether the destination is India or the UAE.

Частые вопросы о процедуре «Bile Duct Cancer Treatment»

What is the cost of Bile Duct Cancer Treatment in India vs the UAE?
The total cost of bile duct cancer treatment varies significantly depending on the disease stage, treatment modality, and the patient's specific molecular profile. In India, at JCI- and NABH-accredited hepatobiliary oncology centers, costs typically range from $6,000 to $22,000 USD. This range covers: biliary drainage procedures (ERCP/PTC stenting) at the lower end (~$3,000–$6,000), locoregional therapies such as TACE or Y-90 SIRT ($6,000–$12,000), and major hepatobiliary surgery — extended hepatectomy with bile duct excision or Whipple procedure — at the upper end ($12,000–$22,000). The cost of targeted therapies such as pemigatinib, futibatinib, or ivosidenib, and immunotherapy with durvalumab, are quoted separately as per-cycle drug costs and are variable. In the UAE, at JCI- and DHA-accredited centers in Dubai and Abu Dhabi, equivalent treatment costs range from $15,000 to $50,000 USD — approximately 50–65% higher than India — reflecting premium hospital infrastructure, higher surgical facility fees, and the UAE's overall healthcare cost structure. India offers the same internationally benchmarked oncological expertise (many surgeons are fellowship-trained in Europe or the US) at the lowest cost, making it the preferred destination for patients prioritizing affordability without compromising quality. The UAE is ideal for patients from the GCC region or those prioritizing proximity, luxury amenities, and premium care environments. GAF Healthcare provides fully itemized, no-obligation cost estimates for both destinations before any commitment is made.
How long do I need to stay in the country before I am fit to fly home after Bile Duct Cancer Treatment?
The required in-country stay before you are medically cleared for international travel depends entirely on which treatment you receive. For biliary stenting (ERCP or PTC) performed as a standalone palliative or pre-operative procedure, you will typically be fit to fly within 7–14 days, provided there are no complications such as post-procedural cholangitis or pancreatitis. For locoregional therapies such as TACE (transarterial chemoembolization) or Y-90 radioembolization (TARE/SIRT) for intrahepatic CCA, the minimum safe in-country stay is 2–3 weeks, allowing monitoring for post-embolization syndrome, biloma formation, and liver function stabilization. For chemotherapy initiation (gemcitabine-cisplatin-durvalumab), patients typically stay 2–3 weeks to complete Cycle 1 and monitor for acute toxicities including nephrotoxicity, myelosuppression, and infusion reactions, before returning home to continue treatment locally. For major hepatobiliary surgery — extended hepatectomy with bile duct excision or pancreaticoduodenectomy (Whipple procedure) — the total in-country stay is 6–8 weeks. Hospital stay alone is 14–21 days, followed by 3–4 weeks of post-discharge recovery at nearby accommodation. Medical clearance for a long-haul flight requires: normalization of serum bilirubin, absence of bile leak or active infection, adequate oral nutritional intake, wound healing, and written physician clearance. Long-haul flights for post-surgical oncology patients also require prophylactic low molecular weight heparin (LMWH) due to elevated VTE risk, which your treating team will prescribe. GAF Healthcare's case managers work closely with your treating surgeon to provide an individualized, evidence-based fit-to-fly certification before your departure is planned.
What is the success rate of Bile Duct Cancer Treatment?
Success rates in bile duct cancer (cholangiocarcinoma) treatment are highly stage-dependent and must be understood in the context of the specific treatment received. For surgically resectable disease treated with curative-intent R0 resection, the 5-year overall survival is approximately 25–40% for perihilar CCA and 20–35% for intrahepatic CCA, rising to 40–50% in node-negative, margin-negative cases at high-volume centers. When adjuvant capecitabine is added post-resection (per BILCAP trial), median overall survival improves to approximately 51.1 months versus 36.4 months with surgery alone. For the highly selected group of perihilar CCA patients undergoing orthotopic liver transplantation following the Mayo Clinic neoadjuvant chemoradiation protocol, 5-year survival rates of 65–70% have been reported — the best outcomes in the disease spectrum for this subgroup. For unresectable or metastatic cholangiocarcinoma treated with the current first-line standard — gemcitabine plus cisplatin plus durvalumab (TOPAZ-1 regimen) — the 24-month overall survival rate is approximately 24.9%, with a median overall survival of 12.8 months, representing a meaningful improvement over chemotherapy alone. Patients with FGFR2 fusion-positive disease treated with pemigatinib or futibatinib in the second-line setting achieve objective response rates of approximately 35%, with median progression-free survival of 6–9 months. IDH1-mutant patients on ivosidenib demonstrate disease control rates of approximately 55%. MSI-H patients treated with pembrolizumab may achieve durable remissions exceeding 2 years in approximately 15–20% of cases. It is important to understand that 'success' in CCA management is measured not only by cure rates — which remain modest in advanced disease — but also by quality of life, duration of biliary patency, freedom from cholangitis, and meaningful time with preserved function. The multidisciplinary, molecularly guided approach at GAF Healthcare's partner centers optimizes all these outcomes.

Как GAF Healthcare помогает выбрать лучшую больницу для «bile duct cancer treatment» в ОАЭ

Найдите лучшие больницы для «bile duct cancer treatment» в ОАЭ

На этой странице представлено 3 больниц в ОАЭ, чтобы вы могли сравнить аккредитацию и специализации в одном месте.

Поддержка, когда она нужна

Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.

Прозрачные, всё включено цены

Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.

Организация визы, поездки и проживания

После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.

Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.

Частые вопросы

Частые вопросы о «Bile Duct Cancer Treatment» в ОАЭ

Сколько больниц направления «Медицинская онкология» представлено в ОАЭ?
Сейчас в ОАЭ представлено 3 больниц.
Как вы выбираете больницы для списка?
Больница появляется на этой странице, если направление «Медицинская онкология» указано среди её специализаций и она находится в ОАЭ. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Сколько стоит лечение в ОАЭ?
Стоимость зависит от больницы, города и конкретного случая. Используйте наш калькулятор стоимости для персональной оценки.
🤔

Остались вопросы?

Наша команда готова ответить на вопросы о «Bile Duct Cancer Treatment» в ОАЭ.

Следующий шаг

Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Bile Duct Cancer Treatment» в ОАЭ.

Свяжитесь с нами, если заметите неточность на этой странице.